Table 3:

Antitumour activity by disease type and subgroup

	Evaluable patients	Overall response	Complete response
Follicular lymphoma
Overall	62	51 (82%; 70–91)	14 (23%; 13–35)
Zandelisib monotherapy	41	32 (78%; 62–89)	9 (22%;11–38)
Zandelisib plus rituximab	21	19 (90%; 70–99)	5 (24%; 8–47)
Refractory to rituximab*	8	7 (88%; 47–100)	1 (13%; 0–53)
Relapsed to rituximab*	13	12 (92%; 64–99)	4 (31%; 9–61)
Continuous dosing group (zandelisib monotherapy)	25	19 (76%; 55–91)	4 (16%; 4–36)
Intermittent dosing group	37	32 (86%; 71–95)	10 (27%; 14–44)
Zandelisib monotherapy	18	14 (78%; 52–94)	5 (28%; 10–53)
Zandelisib plus rituximab	19	18 (95%; 74–100)	5 (26%; 9–51)
Chronic lymphocytic leukaemia or small lymphocytic lymphoma
Overall	20	20 (100%; 83–100)	5 (25%; 9–49)
Zandelisib monotherapy	13	13 (100%; 75–100)	4 (31%; 9–61)
Zandelisib plus rituximab	7	7 (100%; 59–100)	1 (14%; 4–58)
Continuous dosing group (zandelisib monotherapy)	10	10 (100%; 69–100)	3 (30%; 8–65)
Intermittent dosing group	10	10 (100%; 69–100)	2 (20%; 3–57)
Zandelisib monotherapy	4	4 (100%; 40–100)	1 (25%; 6–81)
Zandelisib plus rituximab	6	6 (100%; 54–100)	1 (17%; 4–64)
Marginal zone lymphoma
Zandelisib plus rituximab†	4	4 (100%; 40–100)	1 (25%; 6–81)
Diffuse large B-cell lymphoma
Zandelisib plus rituximab†	9	1 (11%; 3–48)	1 (11%; 3–48)

Data are n or n (%; 95% CI).

^*Post-hoc analysis.

^†All on intermittent dosing.